# Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

> **NCT02453711** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 957 (actual)

## Conditions studied

- Metabolism and Nutrition Disorder
- Obesity

## Interventions

- **DRUG:** semaglutide
- **DRUG:** liraglutide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02453711
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-01
- **Primary completion:** 2017-03-30
- **Final completion:** 2017-04-12
- **Target enrollment:** 957 (ACTUAL)
- **Last updated:** 2020-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02453711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02453711, "Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02453711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*